For participants with obesity and T2DM, GLP-1 RA administration was associated with a lower incidence of MACE (RR 0.89 [0.81–0.98]), whereas SGLT-2 inhibitor administration showed a trend (RR 0.91 [0.83–1.00]). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.